SYSTEMATIC REVIEW OF COST EFFECTIVENESS OF GEFITINIB IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER IN CHINA

被引：1
|
作者：
Hu, C. [1 ]
Huang, L. [1 ]
Zhao, D. [1 ]
Xu, L. [1 ]
机构：
[1] Astrazeneca China, Beijing, Peoples R China
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.1183
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN166
引用
收藏
页码：A459 / A459
页数：1
相关论文
共 50 条
  • [21] Gefitinib for advanced non-small cell lung cancer
    Sim, Esther H. A.
    Yang, Ian A.
    Wood-Baker, Richard
    Bowman, Rayleen V.
    Fong, Kwun M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (01):
  • [22] Gefitinib in advanced non-small cell lung cancer
    Sharma, R
    Boyer, M
    Clarke, S
    Millward, M
    INTERNAL MEDICINE JOURNAL, 2005, 35 (02) : 77 - 82
  • [23] INDIRECT COST IN NON-SMALL CELL LUNG CANCER (NSCLC): A SYSTEMATIC LITERATURE REVIEW
    Schmidt, E.
    Stanisic, S.
    Neumann, M.
    Walzer, S.
    VALUE IN HEALTH, 2010, 13 (07) : A271 - A271
  • [24] A Review of Cost-Effectiveness Studies of Pembrolizumab Regimens for the Treatment of Advanced Non-small Cell Lung Cancer
    Nan Qiao
    Ralph Insinga
    Gilberto de Lima Lopes Junior
    John Cook
    Martin Sénécal
    PharmacoEconomics - Open, 2021, 5 : 365 - 383
  • [25] A Review of Cost-Effectiveness Studies of Pembrolizumab Regimens for the Treatment of Advanced Non-small Cell Lung Cancer
    Qiao, Nan
    Insinga, Ralph
    Lopes Junior, Gilberto de Lima
    Cook, John
    Senecal, Martin
    PHARMACOECONOMICS-OPEN, 2021, 5 (03) : 365 - 383
  • [26] Cost Effectiveness of Treatment With New Agents in Advanced Non-Small-Cell Lung Cancer A Systematic Review
    Bongers, Mathilda L.
    Coupe, Veerle M. H.
    Jansma, Elise P.
    Smit, Egbert F.
    Uyl-de Groot, Carin A.
    PHARMACOECONOMICS, 2012, 30 (01) : 17 - 34
  • [27] Effect of gefitinib challenge to initial treatment with non-small cell lung cancer
    Chen, Xiaofeng
    Li, Wei
    Hu, Xiaoli
    Geng, Yiting
    Wang, Rong
    Yin, Yongmei
    Shu, Yongqian
    BIOMEDICINE & PHARMACOTHERAPY, 2011, 65 (08) : 542 - 546
  • [28] Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: A systematic review
    Feld, Ron
    Sridhar, Srikala S.
    Shepherd, Frances A.
    Mackay, Jean A.
    Evans, William K.
    JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (04) : 367 - 376
  • [29] COST-EFFECTIVENESS OF PRECISION DIAGNOSTIC TESTING AND PRECISION MEDICINE FOR NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW
    Henderson, R.
    Lawler, M.
    Keeling, P.
    French, D.
    Smart, D.
    Finucane, S.
    Sullivan, R.
    VALUE IN HEALTH, 2020, 23 : S33 - S33
  • [30] The cost of non-small cell lung cancer (NSCLC) treatment
    Vergnenegre, A.
    ONCOLOGIE, 2012, 14 (05) : 310 - 315
12345